Literature DB >> 12226687

Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with enterobacter bacteremia.

S-O Lee1, Y S Kim, B N Kim, M-N Kim, J-H Woo, J Ryu.   

Abstract

This retrospective study was conducted to determine the risk factors for resistance to extended-spectrum cephalosporins (ESCs) and to examine the influence of previous use of an aminoglycoside with an ESC on resistance to ESCs in patients with Enterobacter bacteremia from January 1991 through December 2000. A total of 423 episodes of Enterobacter bacteremia among 414 patients were documented during the 10-year study period. Three hundred thirty-two (78%) isolates were Enterobacter cloacae, 72 (17%) Enterobacter aerogenes, and 19 (4%) other Enterobacter species. Causative isolates exhibited resistance to ESCs in 225 episodes and susceptibility in 198 episodes. Nosocomial acquisition was an independent risk factor for resistance to ESCs (odds ratio [OR], 3.4; 95% confidence interval [95%CI], 1.7-6.8). The median number of antibiotics used was significantly greater in cases caused by resistant isolates than in cases caused by susceptible isolates (OR, 1.8; 95%CI, 1.2-2.6). Resistance to ESCs was associated with previous use of any ESC (OR, 5.0; 95%CI, 2.5-10.2). The proportion of resistant episodes in patients treated previously with an aminoglycoside plus an ESC was not different from that in patients treated with an ESC alone. In conclusion, previous use of ESCs was associated with resistance to ESCs in patients with Enterobacter bacteremia; moreover, previous use of an aminoglycoside with an ESC did not significantly decrease the risk of resistance to ESCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226687     DOI: 10.1007/s10096-002-0772-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

Review 1.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

Review 2.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 3.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

4.  Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.

Authors:  Sang-Ho Choi; Jung Eun Lee; Su Jin Park; Seong-Ho Choi; Sang-Oh Lee; Jin-Yong Jeong; Mi-Na Kim; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

5.  Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice.

Authors:  Anniina Keskitalo; Eveliina Munukka; Raine Toivonen; Maija Hollmén; Heikki Kainulainen; Pentti Huovinen; Sirpa Jalkanen; Satu Pekkala
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

6.  Functional Annotation of Hypothetical Proteins From the Enterobacter cloacae B13 Strain and Its Association With Pathogenicity.

Authors:  Supantha Dey; Sazzad Shahrear; Maliha Afroj Zinnia; Ahnaf Tajwar; Abul Bashar Mir Md Khademul Islam
Journal:  Bioinform Biol Insights       Date:  2022-08-06

7.  Extended-spectrum beta-lactamase--producing enterobacteriaceae in the intensive care unit: acquisition does not mean cross-transmission.

Authors:  Mikael Alves; Astrid Lemire; Dominique Decré; Dimitri Margetis; Naïke Bigé; Claire Pichereau; Hafid Ait-Oufella; Jean-Luc Baudel; Georges Offenstadt; Bertrand Guidet; Frédéric Barbut; Eric Maury
Journal:  BMC Infect Dis       Date:  2016-04-13       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.